PT -期刊文章盟玛蒂娜Absinta盟——艾琳蔡玫Cortese AU -路易莎Vuolo盟Govind Nair AU -琼Ohayon AU -亚历山德罗代表我非盟-维托里奥Martinelli AU -罗伯塔Scotti AU -安德里亚Falini盟-布莱恩·r·史密斯盟Avindra Nath盟史蒂文·雅各布森AU -马西莫菲利皮主持盟丹尼尔s帝国TI -患病率LEPTOMENINGEAL对比度增强在多发性硬化症与其他慢性神经炎症疾病(S2.007) DP - 2017年4月18日TA -神经病学PG - S2.007 VI - 88 IP - 16补充4099 - //www.ez-admanager.com/content/88/16_Supplement/S2.007.short 4100 - //www.ez-admanager.com/content/88/16_Supplement/S2.007.full所以Neurology2017 4月18日;首页88 AB -目的:我们的目的是评估的患病率和特异性leptomeningeal增强(LME)在多发性硬化症(MS)相比,各种炎症和非炎症神经疾病评估学术研究在两个医院。背景:Leptomeningeal增强postcontrast T2-FLAIR MRI最近被描述在女士经常发生,与皮质髓鞘脱失和临床进展。设计/方法:在3-tesla postcontrast T2-FLAIR图像、焦钆增强的存在是leptomeningeal评估室254年非ms患者神经条件或亲神经的病毒感染。基于他们的临床诊断,患者分组如下:(1)other-than-MS炎症性神经系统疾病;(2)非炎症神经系统疾病;(3)人类t细胞白血病病毒(HTLV)感染;(4)人类免疫缺陷病毒(HIV)感染;(5)健康志愿者。结果:LME中检测出非MS 56/254例(22%)与74/299(25%)的情况下女士。LME将近4倍更频繁的在非ms炎症性神经疾病(18/51例,35%)比非炎症神经疾病(3/38,8%)和健康志愿者(5/66,8%)。 The highest prevalence of LME was detected in HTLV infection (17/38 cases, 45%), particularly in the setting of HTLV-associated myelopathy (14/25 cases, 56%). LME also frequently occurred in HIV infection (13/61 cases, 21%).Conclusions: Despite its relevance to MS pathology and pathogenesis, LME is not specific to MS, occurring frequently in non-MS inflammatory neurological conditions and especially in those patients with HTLV-associated myelopathy. Overall, this strengthens the notion that LME localizes inflammation-related focal disruption of the blood-meninges barrier and associated scarring.Study Supported by: The Intramural Research Program of NINDS supported this study. Dr Absinta was partially supported by a NMSS postdoctoral fellowship, award #FG 2093-A-1.Disclosure: Dr. Absinta has nothing to disclose. Dr. Cortese has nothing to disclose. Dr. Vuolo has nothing to disclose. Dr. Nair has nothing to disclose. Dr. Ohayon has nothing to disclose. Dr. Meani has nothing to disclose. Dr. Martinelli has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer Schering Pharma, Teva Pharmaceutical Industries Ltd., and sanofi-aventi. Dr. Scotti has nothing to disclose. Dr. Falini has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Nath has nothing to disclose. Dr. Jacobson has nothing to disclose. Dr. Filippi has received personal compensation for activities with Biogen Idec, Excemed, Novartis, and Teva as a consultant and/or speaker. Dr. Reich has received research support from Vertex Pharmaceuticals.